ClinicalTrials.gg

Program

azenosertib

Also written as “Azenosertib” and “ZN-c3”.

Its studies are mostly in Ovarian Neoplasms · Osteosarcoma · Cystadenocarcinoma, Serous · Colorectal Neoplasms · Leukemia, Myeloid, Acute, led by 3 companies.

Furthest: phase 3, since Mar 26, 20269 company-led studies, 2 open or runningNext primary completion: Dec 1, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals72 open or runningphase 3since Mar 26, 2026Nov 4, 2019Dec 1, 2026phase 2 · NCT05128825
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals10 open or runningphase 2since Dec 19, 2022Dec 19, 2022none ahead
Zentera Therapeutics HK10 open or runningphase 1since Jul 12, 2021Jul 12, 2021none ahead

Also a collaborator on its studies: Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2019First study: phase 1 study in Solid TumorNew to K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT04158336 · 274 enrolled · United States
  2. Mar 18, 2021Phase 2 study in Cystadenocarcinoma, SerousK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT04814108 · 92 enrolled · United States, Australia, Canada and more
  3. Mar 25, 2021Phase 1 study in OsteosarcomaK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT04833582 · 31 enrolled · United States, France
  4. Jul 12, 2021Zentera Therapeutics HK's first study: phase 1 study in Solid TumorsNew to Zentera Therapeutics HKZentera Therapeutics HK · NCT04972422 · 38 enrolled · China
  5. Oct 28, 2021Phase 2 study in Ovarian NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05128825 · 310 planned · United States, Australia, Belgium and more
  6. Dec 8, 2021Phase 2 study in Ovarian NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05198804 · 117 enrolled · United States, France
  7. Dec 19, 2022K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals's first study: phase 2 study in Leukemia, Myeloid, AcuteNew to K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05682170 · 40 enrolled · United States
  8. Jan 26, 2023Phase 1 study in Colorectal NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05743036 · 44 enrolled · United States, Australia, Germany and more
  9. Mar 26, 2026Phase 3 study in Ovarian NeoplasmsPhase 3 reachedK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT07546500 · 420 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 1, 2026Primary completion: phase 2 study in Ovarian NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05128825
  2. May 31, 2028Primary completion: phase 3 study in Ovarian NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT07546500

TargetBeta

WEE1 →read by rule
“Serine/threonine-protein kinase WEE1 inhibitor”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07546500Ovarian Neoplasms · United States, Argentina, Australia and more3RecruitingK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsMay 31, 2028420
NCT05743036Colorectal Neoplasms · United States, Australia, Germany and more1TerminatedK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsJul 16, 202444
NCT05682170Leukemia, Myeloid, Acute · United States2TerminatedK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsJul 2, 202440
NCT05198804Ovarian Neoplasms · United States, France2CompletedK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsOct 15, 2025117
NCT05128825Ovarian Neoplasms · United States, Australia, Belgium and more2RecruitingK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsDec 1, 2026310
NCT04972422Solid Tumors · China1UNKNOWNZentera Therapeutics HKJun 30, 202238
NCT04833582Osteosarcoma · United States, France1CompletedK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsAug 30, 202331
NCT04814108Cystadenocarcinoma, Serous · United States, Australia, Canada and more2CompletedK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsOct 22, 202592
NCT04158336Solid Tumor · United States1CompletedK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsMay 6, 2025274

How it is read

Names in the registry

  • “Azenosertib”, 5 entries
  • “ZN-c3”, 3 entries
  • “azenosertib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.